The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective

Minerva Medica

Volumn 94, Issue 4, 2003, Pages 251-258

  Kurland, L ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antihypertensive agents; Hypertension diagnosis; Hypertension, drug therapy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; IRBESARTAN;

CARDIOVASCULAR DISEASE; GENOTYPE; HEREDITY; HERITABILITY; HYPERTENSION; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; REVIEW; STROKE;

ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CYTOCHROME P-450 CYP2D6; HUMANS; HYPERTENSION; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES;

EID: 0242443216     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Hamilton M, Pickering G, Fraser Roberts JA, Sowry GSC. The etiology of essential yypertension. Clin Sci 1954;13:273-304.
2. Miall W, Oldham P. A study of arterial blood pressure and its inheritance in a sample of the general population. 1955.p.459-88.
3. Johnson B, Epstein F, Kjelsberg MO. Distributions and familial studies of blood pressure and serum cholesterol jevels in a total community-techumseh. Michigan J Chron Dis 1964;18:147-60.
4. Miall WE, Heneage P, Khosla T, Lovell HG, Moore F. Factors influencing the degree of resemblance in arterial pressure of close relatives. Clin Sci 1967;33:271-83.
5. Havlik RJ, Garrison RJ, Feinleib M, Kannel WB, Castelli WP, McNamara PM. Blood pressure aggregation in families. Am J Epidemiol 1979;110:304-12.
6. Miall W, Oldham P. The hereditary factor in arterial blood-pressure. Br Med J 1963;1:75.
7. Harrap SB. Hypertension: genes versus environment. Lancet 1994;344:169-71.
8. Havlik RJ, Garrison RJ, Katz SH, Ellison RC, Feinleib M, Myrianthopoulos NC. Detection of genetic variance in blood pressure of seven-year-old twins. Am J Epidemiol 1979:109:512-6.
9. Slattery ML, Bishop DT, French TK, Hunt SC, Meikle AW, Williams RR. Lifestyle and blood pressure levels in male twins in Utah. Genet Epidemiol 1988;5:277-87.
10. Hunt SC, Hasstedt SJ, Kuida H, Stults BM, Hopkins PN, Williams RR. Genetic heritability and common environmental components of resting and stressed blood pressures, lipids, and body mass index in Utah pedigrees and twins. Am J Epidemiol 1989;129:625-38.
11. Ditto B. Familial influences on heart rate, blood pressure, and self-report anxiety responses to stress: results from 100 twin pairs. Psychophysiology 1993;30: 635-45.
12. Fagard R, Brguljan J, Staessen J, Thijs L, Derom C, Thomis M et al. Heritability of conventional and ambulatory blood pressures. A study in twins. Hypertension 1995;26 6 Pt 1:919-24.
13. Pausova Z, Gossard F, Gaudet D, Tremblay J, Kotchen TA, Cowley AW et al. Heritability estimates of obesity measures in siblings with and without hypertension. Hypertension 2001;38:41-7.
14. Hong Y, de Faire U, Heller DA, McClearn GE, Pedersen N. Genetic and environmental influences on blood pressure in elderly twins. Hypertension 1994;24:663-70.
15. Rice T, Province M, Perusse L, Bouchard C, Rao DC. Cross-trait familial resemblance for body fat and blood pressure: familial correlations in the Quebec Family Study. Am J Hum Genet 1994;55:1019-29.
16. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-83.
17. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-9. Erratum in: Hypertension 1996;27:1192.
18. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995;26:60-9. Erratum in: Hypertension 1996;27:1192.
19. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997;157:2413-46.
20. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. J Hypertens 1998;16: 127-37.
21. Neal B, MacMahon S. The World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration: prospective collaborative overviews of major randomized trials of blood pressure-lowering treatments. Curr Hypertens Rep 1999;1:346-56.
22. Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-64.
23. Laragh JH, Lamport B, Sealey J, Alderman MH. Diagnosis exjuvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988;12:223-6.
24. Lind L, Berne C, Andersson PE, Hanni A, Lithell H. Is insulin resistance a predictor of the blood pressure response to anti-hypertensive treatment? J Hum Hypertens 1995;9:759-63.
25. Attwood S, Bird R, Burch K, Casadei B, Coats A, Conway J et al. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens 1994;12:1053-60.
26. Case DB, Wallace JM, Keim HJ, Weber MA, Sealey JE, Laragh JH. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med 1977;296:641-6.
27. Laragh JH, Letcher RL, Pickering TG. Renin profiling for diagnosis and treatment of hypertension. JAMA 1979;241:151-6.
28. Buhler FR. Antihypertensive treatment according to age, plasma renin and race. Drugs 1988;35:495-503.
29. Oshima T, Matsuura H, Matsumoto K, Kido K, Kajiyama G. Role of cellular calcium in salt sensitivity of patients with essential hypertension. Hypertension 1988; 11(6 Pt 2):703-7.
30. Laragh JH. Renin profiling for diagnosis, risk assessment, and treatment of hypertension [clinical conference]. Kidney Int 1993;44:1163-75.
31. Hughes H, Biehl J, Jones AP, Schimth LH. Metabolism of isoniazid in man as related to the occurence of peripheral neuritis. Am Rev Tuberc 1954;70:266.
32. Carson P, Flanagan C, Ickes CE, Alving AS. Enzymatic deficiency in primaquine sensitive erythrocytes. Science 1956;124:484.
33. Kalow W. Familial Incidence of low pseudocholinesterase level. Lancet 1956;211:576.
34. Evans D, Manley K, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J 1960;2:485-91.
35. Motulsky A. Drug reactions, enzymes and biochemical genetics. JAMA 1957;165:835-7.
36. Vogel F. Moderne probleme der humnagenetik. Ergebn Inn Med Kinderheilk 1959;12:52-125.
37. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405:857-65.
38. McLeod HL, Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001;41:101-21.
39. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 2001; 286:2270-9.
40. Roses AD. Pharmacogenetics. Hum Mol Genet 2001;10:2261-7.
41. Evans WE, McLeod HL. Pharmaco-enomics-drug disposition, drug targets, and side effects. N Engl J Med 2003;348:538-49.
42. Lindpaintner K. Pharmacogenetics and the future of medical practice. J Mol Med 2003;81:141-53.
43. Turner ST, Schwartz GL, Chapman AB, Hall WD, Boerwinkle E. Antihypertensive pharmacogenetics: getting the right drug into the right patient. J Hypertens 2001;19:1-11.
44. http://drnelson.utmem.edu/CytochromeP450.html
45. www.imm.ki.se/CYPalleles/CYP2D6.htm
46. Marshall A. Laying the foundations for personalized medicines. Nat Biotechnol 1997;15:954-7.
47. Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Science 1998;281:1820-1.
48. http://medicine.iupui.edu/flockhart/.
49. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997;7:361-7.
50. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-9.
51. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
52. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and 1359L mutant forms. Arch Biochem Biophys 1996;333:447-58.
53. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997;7:203-10.
54. Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K et al. The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. J Hypertens 2002;20:2089-93.
55. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997;349:1353-7.
56. Turner ST, Schwartz GL, Chapman AB, Boerwinkle E. C825T polymorphism of the G protein beta(3)-subunit and antihypertensive response to a thiazide diuretic. Hypertension 2001;37(2 Part 2):739-43.
57. Hernandez-Hernandez R, Sosa-Canache B, Sosa-Canache B, Velasco M, Armas-Hernandez MJ, Armas-Padilla MC et al. Angiotensin II receptor antagonists role in arterial hypertension. J Hum Hypertens 2002;16 (Suppl 1):S93-9.
58. Malmqvist K, Kahan T, Edner M, Held C, Hagg A, Lind L et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001;19:1167-76.
59. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman KP et al. Angiotensin converting enzyme gene polymorphism predicts blood pressure resonse to angiotensin II receptor type I antagonist treatment in hypertensive patients. J Hypertens 2001;19:1783-7.
60. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P et al. Aldosterone synthase (CYP11B2) -344 C/T polymorphism is related to antihypertensive response: result from the Swedish Irbesartan Left Ventricular. Hypertrophy Investigation versus Atenolol (SILVHIA) trial. Am J Hypertens 2002;15:389-93.
61. Kurland L, Melhus H, Karlsson J, Kahan T, Malmqvist K, Ohman P et al. Polymorphisms in the angiotensinogen and angiotensin II type 1 receptor gene are related to change in left ventricular mass during antihypertensive treatment: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) trial. J Hypertens 2002;20:657-63.
62. Danser AH, Schunkert H. Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. Eur J Pharmacol 2000;410:303-16.
63. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001;409:928-33.
64. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG et al. The sequence of the human genome. Science 2001;291:1304-51.
65. Liljedahl U, Karlsson J, Melhus H, Kurland L, Lindersson M, Kahan T et al. A microarray minisequencing system for pharmacogeentic profiling of antihypertensive drug response. Pharmacogenetics 2003;13:7-17.
66. Shi MM. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies. Clin Chem 2001;47:164-72.
67. Syvanen AC. Accessing genetic variation: genotyping single nucleotide polymorphisms. Nat Rev Genet 2001;2:930-42.